Androgen Deprivation Therapy Not Linked With Risk of Dementia

Share this content:
Androgen deprivation therapy use among patients with prostate cancer was not associated with an increased risk of dementia
Androgen deprivation therapy use among patients with prostate cancer was not associated with an increased risk of dementia

Androgen deprivation therapy (ADT) use among patients with prostate cancer was not associated with an increased risk of dementia, according to a study published in the Journal of Clinical Oncology.1

Researchers conducted a cohort study of 30,903 men with newly-diagnosed, non-metastatic prostate cancer through the United Kingdom's Clinical Practice Research Datalink to examine any possible link between ADT use and increased risk of dementia in this patient population.

“Recent observational studies have associated the use of ADT with an increased risk of dementia and Alzheimer's disease, but these studies had limitations,” the authors noted.

The researchers found that ADT use was not associated with increased dementia risk compared to non-use. In total, 799 patients had newly diagnosed with dementia for every 1000 person-years upon a mean follow-up of 4.3 years.

RELATED: Developing microRNA Biomarkers for Prostate Cancer

No single ADT type or cumulative duration of use was associated with an increased dementia risk upon secondary analyses.

Reference

  1. Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen deprivation therapy and the risk of dementia in patients with prostate cancer. J Clin Oncol. 2016 Nov 21. doi: 10.1200/JCO.2016.69.6203 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters